SCHEMBL2334396

SCHEMBL2334396

O=C(O)C1C2CCC(O2)C1C(=O)N1CCNCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TFPI2 P48307 11/20 0.73
PPP5C P53041 2/20 0.67
NPY4R P50391 2/20 0.67
PPP2CA P67775 1/20 0.67
KDM4E B2RXH2 1/20 0.57
GMNN O75496 1/20 0.57
LMNA P02545 1/20 0.57
PMP22 Q01453 1/20 0.57
TP53 P04637 1/20 0.57
TSHR P16473 1/20 0.57
NFKB1 P19838 1/20 0.57
THPO P40225 1/20 0.57
CHRNB2 P17787 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA4 P43681 1/20 0.50
CHRNB3 Q05901 1/20 0.50
CHRNA6 Q15825 1/20 0.50
PPM1B O75688 2/20 0.45
PTPN1 P18031 2/20 0.45
PPP1CC P36873 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13311572 1.00 TFPI2 (0.73) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL9880150 1.00 TFPI2 (0.73) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL2330162 0.87 TFPI2 (0.55) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL2330157 0.85 TFPI2 (0.53) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL13311599 0.84 TFPI2 (0.93) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL9880174 0.83 TFPI2 (0.90) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL2332631 0.83 TFPI2 (0.77) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL18073223 0.83 TFPI2 (0.90) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL13311562 0.83 TFPI2 (0.90) TFPI2PPP5CNPY4RPPP2CAKDM4E
SCHEMBL13001884 0.82 TFPI2 (0.49) TFPI2PPP5CNPY4RPPP2CAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2019-09-03 US disclosed
US-20180370983-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2018-12-27 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 US disclosed
EP-2124550-B1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY INC (US) 2017-04-19 EP disclosed
EP-2124550-B1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY INC (US) 2017-04-19 EP disclosed
US-20160264593-A1 PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER LIXTE BIOTECHNOLOGY, INC. 2016-09-15 US disclosed
US-9079917-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2015-07-14 US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
WO-2008097561-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885
US-20160264593-A1 PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER DUSP1, PPP5C, DUSP15 TFPI2 320/4885PPP5C 2/4885NPY4R 2744/4885
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use HCCS, VHL, OXA1L TFPI2 4843/4885PPP5C 2860/4885NPY4R 3326/4885
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885
US-20180370983-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885NPY4R 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.